EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model

Daniela Zizioli iD, Sara Ferretti, Giorgio Tiecco iD, Luca Mignani, Eugenio Monti iD, Francesco Castelli iD, Eugenia Quiros-Roldan iD, Isabella Zanella iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241411664 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Daniela Zizioli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Brescia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the past, one of the most widely used non-nucleoside reverse transcriptase inhibitors (NNRTI) in first-line antiretroviral therapy (ART) of HIV infection was efavirenz (EFV), which is already used as a cost-effective treatment in developing countries due to its efficacy, tolerability, and availability. However, EFV also demonstrates several adverse effects, like hepatotoxicity, altered lipid profile, neuropsychological symptoms, and behavioral effects in children after in utero exposure. In 2018, another NNRTI, doravirine (DOR), was approved due to its similar efficacy but better safety profile. Preclinical safety studies demonstrated that DOR is not genotoxic and exhibits no developmental toxicity or effects on fertility in rats. Zebrafish (Danio rerio) embryos have been widely accepted as a vertebrate model for pharmacological and developmental studies. We used zebrafish embryos as an in vivo model to investigate the developmental toxicity of DOR compared to EFV. After exposure of the embryos to the drugs from the gastrula stage up to different developmental stages (30 embryos for each arm, in three independent experiments), we assessed their survival, morphology, hatching rate, apoptosis in the developing head, locomotion behavior, vasculature development, and neutral lipid distribution. Overall, DOR showed a better safety profile than EFV in our model. Therapeutic and supra-therapeutic doses of DOR induced very low mortality [survival rates: 92, 90, 88, 88, and 81% at 1, 5, 10, 25, and 50 μM, respectively, at 24 h post fecundation (hpf), and 88, 85, 88, 89, and 75% at the same doses, respectively, at 48 hpf] and mild morphological alterations compared to EFV exposure also in the sub-therapeutic ranges (survival rates: 80, 77, 69, 63, and 44% at 1, 5, 10, 25, and 50 μM, respectively, at 24 hpf and 72, 70, 63, 52, and 0% at the same doses, respectively, at 48 hpf). Further, DOR only slightly affected the hatching rate at supra-therapeutic doses (97, 98, 96, 87, and 83% at 1, 5, 10, 25, and 50 μM, respectively, at 72 hpf), while EFV already strongly reduced hatching at sub-therapeutic doses (83, 49, 11, 0, and 0% at 1, 5, 10, 25, and 50 μM, respectively, at the same time endpoint). Both DOR at therapeutic doses and most severely EFV at sub-therapeutic doses enhanced apoptosis in the developing head during crucial phases of embryo neurodevelopment and perturbed the locomotor behavior. Furthermore, EFV strongly affected angiogenesis and disturbed neutral lipid homeostasis even at sub-therapeutic doses compared to DOR at therapeutic concentrations. Our findings in zebrafish embryos add further data confirming the higher safety of DOR with respect to EFV regarding embryo development, neurogenesis, angiogenesis, and lipid metabolism. Further studies are needed to explore the molecular mechanisms underlying the better pharmacological safety profile of DOR, and further human studies are required to confirm these results in the zebrafish animal model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsHumansChildAnimalsRatsZebrafishReverse Transcriptase InhibitorsLipidsEmbryo, NonmammalianAlkynesCyclopropanesBenzoxazinesPyridonesTriazoles

Stichwörter der Autor:innen

HIVNNRTIdevelopmental safetydoravirineefavirenznon-nucleoside reverse transcriptase inhibitorszebrafish embryo

Substanzen

Anti-HIV AgentsReverse Transcriptase InhibitorsLipidsefavirenzAlkynesCyclopropanesBenzoxazinesdoravirinePyridonesTriazoles

Autor:innen und Institutionen

  • Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
  • Division of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
  • Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.
  • Cytogenetics and Molecular Genetics Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.

ORCID-Profile: Daniela Zizioli, Giorgio Tiecco, Eugenio Monti, Francesco Castelli, Eugenia Quiros-Roldan, Isabella Zanella

Förderung

  • University of Brescia

Zitieren

APA

Zizioli, D., Ferretti, S., Tiecco, G., Mignani, L., Monti, E., Castelli, F., Quiros-Roldan, E., & Zanella, I. (2023). Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241411664

Vancouver

Zizioli D, Ferretti S, Tiecco G, Mignani L, Monti E, Castelli F, et al. Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241411664

BibTeX
@article{Zizioli2023,
  author = {Zizioli, Daniela and Ferretti, Sara and Tiecco, Giorgio and Mignani, Luca and Monti, Eugenio and Castelli, Francesco and Quiros-Roldan, Eugenia and Zanella, Isabella},
  title = {Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241411664}
}
Kostenlos starten →